In vitro characterization of the furin inhibitor MI-1851: Albumin binding, interaction with cytochrome P450 enzymes and cytotoxicity
Open Access
- 17 May 2022
- journal article
- research article
- Published by Elsevier in Biomedicine & Pharmacotherapy
- Vol. 151, 113124
Abstract
No abstract availableKeywords
Funding Information
- Nemzeti Kutatási Fejlesztési és Innovációs Hivatal (124522)
- Nemzeti Kutatási, Fejlesztési és Innovaciós Alap
- Nemzeti Kutatási és Technológiai Hivatal
- Innovációs és Technológiai Minisztérium
This publication has 23 references indexed in Scilit:
- A Multibasic Cleavage Site in the Spike Protein of SARS-CoV-2 Is Essential for Infection of Human Lung CellsMolecular Cell, 2020
- SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked by a Clinically Proven Protease InhibitorCell, 2020
- Interaction of Mycotoxin Alternariol with Serum AlbuminInternational Journal of Molecular Sciences, 2019
- Interaction of Chrysin and Its Main Conjugated Metabolites Chrysin-7-Sulfate and Chrysin-7-Glucuronide with Serum AlbuminInternational Journal of Molecular Sciences, 2018
- Interactions of zearalenone and its reduced metabolites α-zearalenol and β-zearalenol with serum albumins: species differences, binding sites, and thermodynamicsMycotoxin Research, 2018
- Optimization of Substrate‐Analogue Furin InhibitorsChemMedChem, 2017
- The biology and therapeutic targeting of the proprotein convertasesNature Reviews Drug Discovery, 2012
- Potent Inhibitors of Furin and Furin-like Proprotein Convertases Containing Decarboxylated P1 Arginine MimeticsJournal of Medicinal Chemistry, 2009
- The spike protein of SARS-CoV — a target for vaccine and therapeutic developmentNature Reviews Microbiology, 2009
- Host cell proteases controlling virus pathogenicityTrends in Microbiology, 1994